NCT01881347.
Trial name or title | Acronym: — |
Methods |
Type of trial: efficacy trial Allocation: randomised Intervention model: cross‐over assignment Masking: double‐blinded (participants, caregiver, investigator, outcomes assessor) Primary purpose: basic science |
Participants |
Condition: type 2 diabetes mellitus Enrolment: estimated 50 Inclusion criteria
Exclusion criteria
|
Interventions |
Intervention(s): resveratrol supplement (100 mg daily for 2 weeks followed by 300 mg daily for 2 weeks) Comparator(s): placebo |
Outcomes |
Primary outcome(s): change from baseline in brachial artery flow‐mediated dilation Secondary outcome(s): change from baseline in fingertip peripheral arterial tonometry, change from baseline in carotid femoral pulse wave velocity, change from baseline in reactive hyperaemia Other outcome(s): change from baseline in serum glucose, change from baseline in serum insulin, change from baseline in mononuclear cell mitochondrial DNA damage, change from baseline in mononuclear cell mitochondrial mass, change from baseline in mononuclear cell mitochondrial production of reactive oxygen species, change from baseline in endothelial cell gene expression, change from baseline in endothelial cell protein expression |
Starting date |
Trial start date: June 2013 Trial completion date: June 2016 |
Contact information | Responsible party/principal investigator: Joseph A Vita, MD, Boston University (Contact: Monika Holbrook: monica.holbrook@bmc.org) |
Study identifier | Trial identifier:NCT01881347 |
Official title | Dose response evaluation of resveratrol supplementation on cerebrovascular function, mood and cognitive performance in type 2 diabetes mellitus (T2DM) |
Stated purpose of study | Quote: "a dose response evaluation of resveratrol supplementation on cerebrovascular function, mood and cognitive performance in type 2 diabetes mellitus" |
Notes |